Published in Br J Haematol on June 01, 2002
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study. BMC Neurol (2012) 0.78
Fish as bioreactors: transgene expression of human coagulation factor VII in fish embryos. Mar Biotechnol (NY) (2004) 0.78
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet (2003) 5.82
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet (2002) 4.19
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? Blood Coagul Fibrinolysis (2009) 1.43
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol (2002) 1.35
Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol (2002) 1.32
Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol (2008) 1.01
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med (2013) 0.96
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost (2010) 0.95
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leuk Res (2006) 0.92
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. Am J Hematol (2013) 0.91
High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica (2003) 0.90
Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma (2002) 0.89
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost (2012) 0.88
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol (2002) 0.87
In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol (2004) 0.87
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med (2004) 0.86
Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol (2009) 0.85
Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy. Transfus Apher Sci (2012) 0.84
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis (2004) 0.84
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost (2004) 0.83
Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV. Blood Cells Mol Dis (2007) 0.83
Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol (2009) 0.82
Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor. Blood Coagul Fibrinolysis (2011) 0.80
Evaluation of five staging systems in 470 patients with multiple myeloma. Haematologica (2006) 0.80
Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer (2014) 0.79
Determination of lipase catalytic activity in two reference materials: BCR 693 and BCR 694 by titrimetry at constant pH. Clin Chem Lab Med (2004) 0.79
Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol (2013) 0.78
Standard measurement of clot-bound thrombin by using a chromogenic substrate for thrombin. Thromb Res (2004) 0.78
beta(S)-Globin gene cluster haplotypes in the West Bank of Palestine. Hemoglobin (2009) 0.78
Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina. Br J Haematol (2003) 0.78
The significance of endothelial heterogeneity in thrombosis and hemostasis. Semin Thromb Hemost (2010) 0.78
Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model. Hematology (2007) 0.76
Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes. Blood Coagul Fibrinolysis (2008) 0.76
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol (2007) 0.76
Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol (2006) 0.75
Interindividual variability of in vitro response to anticoagulants. Thromb Res (2010) 0.75
Is APC resistance a risk factor for venous thromboembolism in patients over 70 years? Thromb Haemost (2002) 0.75
In vitro effect of melagatran and lepirudin on clot-bound thrombin. Thromb Res (2003) 0.75
Heritable Thrombophilia and Pregnancy Associated Thrombosis. Turk J Haematol (2002) 0.75
Decreased procoagulant phospholipids in patients treated by vitamin K antagonists. Thromb Res (2012) 0.75
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X. Blood Coagul Fibrinolysis (2005) 0.75
On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. Blood Coagul Fibrinolysis (2003) 0.75
[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress]. Presse Med (2012) 0.75
Decreased activity of soluble thrombomodulin and plasma procoagulant phospholipids in childhood bone marrow transplantation with severe complications. Thromb Res (2011) 0.75
[New anticoagulants: mechanism of action and therapeutic targets]. Tunis Med (2005) 0.75
Preparation and characterization of reference materials for human pancreatic lipase: BCR 693 (from human pancreatic juice) and BCR 694 (recombinant). Clin Chem Lab Med (2003) 0.75